Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Rhythm Pharmaceuticals (RYTM) Stock Price & Analysis
401 Followers
RYTM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.50 - $52.57
Previous Close$38.11
Volume439.03K
Average Volume (3M)602.03K
Market Cap
$2.29B
Enterprise Value$1.99B
Total Cash (Recent Filing)$299.26M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)-11.9
Beta1.26
Next Earnings
Apr 30, 2024EPS Estimate
-$2.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding60,140,495
10 Day Avg. Volume514,221
30 Day Avg. Volume602,031
Standard Deviation0.35
R-Squared0.08
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)14.24
Price to Sales (P/S)97.83
Price to Cash Flow (P/CF)-19.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue47.79
Enterprise Value/Gross Profit92.73
Enterprise Value/Ebitda-15.84
Forecast
1Y Price Target
$56.29Price Target Upside47.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Rhythm Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market ExpansionSecured approval to add 12 Japanese hypothalamic obesity patients to an ongoing pivotal trial, indicating potential market expansion.
Product LaunchImcivree has launched in Germany for BBS and is reimbursed in France, and recently approved in Italy and Spain for treatment of BBS.
Revenue GrowthAnalyst expects ~$900M peak revenues out of Japan, a new revenue source that wasn't previously anticipated.
Bears Say
Policy ChangeA state changed their Medicaid Imcivree coverage policy, resulting in patients moving to free drug, which could signal potential future losses in revenue.
Revenue ForecastAnalyst adjusts revenue projections downward, reflecting a cautious stance on the growth trajectory due to reimbursement challenges and a tepid ex-US launch.
Sales PerformanceImcivree sales falling short of expectations could reflect a concerning trend for future revenue, especially if prescription numbers continue to decline.
---
Ownership Overview
20.46% Insiders
28.93% Mutual Funds
13.62% Other Institutional Investors
36.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $15.50 and its highest was $52.57 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2024 which is in 11 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Feb 22, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.706 by $0.006.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -$2.36.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 60,140,495 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.706. Following the earnings report the stock price went down -9.732%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Among the largest hedge funds holding Rhythm Pharmaceuticals Inc’s share is PRIMECAP Management Co. It holds Rhythm Pharmaceuticals Inc’s shares valued at 370M.
---
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.29 (47.70% Upside)
$56.29 (47.70% Upside)
Blogger Sentiment
Neutral
RYTM Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.01%
12-Months-Change
Fundamentals
Return on Equity
-85.10%
Trailing 12-Months
Asset Growth
-13.00%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q4 2024
0:00 / 0:00
---
RYTM Stock 12 Months Forecast
Average Price Target
$56.29
▲(47.70% Upside)
Technical Analysis
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+70.46%
reiterated a buy rating 10 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +70.46% per trade.
---